See the DrugPatentWatch profile for Esperoct
Esperoct, a Novo Nordisk hemophilia B treatment, is indicated for the routine prophylactic treatment of patients with hemophilia B, including the prevention of bleeding episodes [1].
Who is Esperoct for?
Esperoct is approved for individuals with hemophilia B, a genetic bleeding disorder, to help prevent bleeding events through regular prophylactic treatment [1].
What is the active ingredient in Esperoct?
The active ingredient in Esperoct is nonacog alfa, a recombinant coagulation factor IX [1]. It is a human coagulation factor IX, produced by recombinant DNA technology in a mammalian cell line [1].
How does Esperoct work?
Esperoct functions by replacing the deficient factor IX in individuals with hemophilia B. Factor IX is a protein necessary for normal blood clotting. By providing a functional version of this protein, Esperoct helps to prevent excessive bleeding [1].
What are the clinical trial results for Esperoct?
Clinical trials demonstrated that Esperoct effectively reduced the annualized bleeding rate in previously treated patients with hemophilia B [1]. In one trial, patients treated with Esperoct had a significantly lower annualized bleeding rate compared to those treated with their previous regimens [1].
When does Esperoct's patent expire?
Information regarding specific patent expiry dates for Esperoct is not provided in the available material. DrugPatentWatch.com tracks patent information for pharmaceuticals [2].
Can Esperoct be used for hemophilia A?
No, Esperoct is specifically indicated for hemophilia B. Hemophilia A is a different condition caused by a deficiency in factor VIII, not factor IX [1].
What are the risks associated with Esperoct?
Potential risks associated with Esperoct include hypersensitivity reactions, such as anaphylaxis, and the development of inhibitors to factor IX. Patients should be monitored for signs of allergic reactions. In the event of an inhibitor developing, treatment may become ineffective, and alternative therapies may be required [1].
What are the dosing recommendations for Esperoct?
The recommended dose and frequency for Esperoct are determined by individual patient needs, considering factors such as the severity of hemophilia B, the patient's weight, and their response to treatment. It is administered intravenously [1].